NCCTG
NORTH CENTRAL CANCER TREATMENT GROUP

Date: July 27, 2007

To: NCCTG Primary Clinical Research Associates

From: Janis Wobschall
Protocol Development Coordinator

Re: N0321, Phase I/II Study of PS-341 in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC)

The Pathology Reporting Form has been revised as follows:

The following line added within the "III. Signatures" box at the bottom of the form: Block/Slide Number(s) to be used for research/banking:_____

The Pathology Submission Form has been revised as follows:

- Clarification that form is used to update the Outstanding Materials Report has been added to the header
- Time point of form submission defined
- "Date sent:" changed to "Date specimen shipped:"
- Reviewer (name) and Membership of Reviewer (location were combined to one line which collects both name of reviewer(s) and location(s)
- Contact information box added

If you have any questions, please feel free to contact me at 507/284-4852.

JW/dg
Enclosure